Navitas Life Sciences buys up KAI Research, adding to later-stage trial offerings

Syringe injection vaccine needle
Navitas Life Sciences and KAI Research will combine to offer more "complex clinical deals." (Pixabay)

Contract research organization KAI Research has been snapped up by fellow CRO Navitas Life Sciences as it looks to boost its study offerings.

Specifically, the buy, financial details of which have not been shared, will see Navitas expand its phase 2 and 3 trial work in North America while adding to its current capabilities in Europe and the Asia-Pacific region.

The integration of KAI into Navitas will also help “support larger and more complex clinical deals with addition of sites and local clinical trial management capabilities in U.S.,” it said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Given KAI’s focus, the deal also strengthens Navitas’ therapeutic expertise in mental health, musculoskeletal diseases, neurological disorders, pain, diabetes, infectious diseases and oncology.

Srinivasan H R, managing director of Navitas, said: “We are on track in terms of our acquisitions, KAI Research will further strengthen our capabilities in clinical services and expand our therapeutic expertise. Through this acquisition, we also gain a unique standpoint in serving Federal agencies like FDA, NIH, CDC, Department of Defense etc.

“Together, we intend to create a world class enterprise making meaningful strides in our ability to deliver improved trial outcomes to the bio pharma landscape. The addition of KAI’s capabilities translates to global trial capabilities across North America, Europe and APAC markets. Combining these operational and TA capabilities with our proprietary AI driven OneClincial platform allows us to be a great partner to small and mid-tier customers as well as to large pharma.”

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.